WO2023215746A3 - Anti-alppl2 antibodies and chimeric antigen receptors, and compositions and methods of use - Google Patents

Anti-alppl2 antibodies and chimeric antigen receptors, and compositions and methods of use Download PDF

Info

Publication number
WO2023215746A3
WO2023215746A3 PCT/US2023/066496 US2023066496W WO2023215746A3 WO 2023215746 A3 WO2023215746 A3 WO 2023215746A3 US 2023066496 W US2023066496 W US 2023066496W WO 2023215746 A3 WO2023215746 A3 WO 2023215746A3
Authority
WO
WIPO (PCT)
Prior art keywords
alppl2
methods
agents
compositions
antibodies
Prior art date
Application number
PCT/US2023/066496
Other languages
French (fr)
Other versions
WO2023215746A2 (en
WO2023215746A9 (en
Inventor
Anthony B. COOPER
Colleen COOPER
Rebecca ARGYROS
Original Assignee
Javelin Oncology, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Javelin Oncology, Inc. filed Critical Javelin Oncology, Inc.
Publication of WO2023215746A2 publication Critical patent/WO2023215746A2/en
Publication of WO2023215746A3 publication Critical patent/WO2023215746A3/en
Publication of WO2023215746A9 publication Critical patent/WO2023215746A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464463—Phosphatases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001—Alkaline phosphatase (3.1.3.1)

Abstract

The disclosure provides anti-ALPPL2 agents such as anti-ALPPL2 antibodies (Abs), antigen-binding Ab fragments, multi-specific Abs and antigen-binding Ab fragments, antibody-drug conjugates (ADCs), and chimeric antigen receptors (CARs). The disclosure also provides polynucleotides and vectors encoding, cells and pharmaceutical compositions comprising such anti-ALPPL2 agents and/or polynucleotides. The present disclosure further relates to methods of treating a subject using such anti-ALPPL2 agents and compositions, and to methods of treating, preventing, or diagnosing a disease such as cancer and methods of stimulating an immune response. Also provided are methods of producing such anti-ALPPL2 agents and cells.
PCT/US2023/066496 2022-05-02 2023-05-02 Anti-alppl2 antibodies and chimeric antigen receptors, and compositions and methods of use WO2023215746A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263337242P 2022-05-02 2022-05-02
US63/337,242 2022-05-02

Publications (3)

Publication Number Publication Date
WO2023215746A2 WO2023215746A2 (en) 2023-11-09
WO2023215746A3 true WO2023215746A3 (en) 2023-12-07
WO2023215746A9 WO2023215746A9 (en) 2024-02-15

Family

ID=88647141

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/066496 WO2023215746A2 (en) 2022-05-02 2023-05-02 Anti-alppl2 antibodies and chimeric antigen receptors, and compositions and methods of use

Country Status (1)

Country Link
WO (1) WO2023215746A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013174003A1 (en) * 2012-05-24 2013-11-28 Mountgate Group Limited Compositions and methods related to prevention and treatment of rabies infection
WO2018229530A1 (en) * 2017-06-14 2018-12-20 Adicet Bio Inc. Antibodies capable of binding hla-a2/tyrd in an hla restricted manner and uses thereof
US20210236650A1 (en) * 2015-11-30 2021-08-05 The Regents Of The University Of California Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013174003A1 (en) * 2012-05-24 2013-11-28 Mountgate Group Limited Compositions and methods related to prevention and treatment of rabies infection
US20210236650A1 (en) * 2015-11-30 2021-08-05 The Regents Of The University Of California Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
WO2018229530A1 (en) * 2017-06-14 2018-12-20 Adicet Bio Inc. Antibodies capable of binding hla-a2/tyrd in an hla restricted manner and uses thereof

Also Published As

Publication number Publication date
WO2023215746A2 (en) 2023-11-09
WO2023215746A9 (en) 2024-02-15

Similar Documents

Publication Publication Date Title
WO2021260209A3 (en) Ccr8 antibodies and uses thereof
HRP20192134T1 (en) Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
RS20050795A (en) Recombinant antibodies and fragments recognising gangloside n-glycolyl-gm3 and use thereof in the diagnosis and treatment of tumours
JP2020513786A5 (en)
WO2006116592A3 (en) Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
CN107106683A (en) Molecule construct containing targeting with effect component
EP0586002A3 (en) Monoclonal antibodies recognizing the epidermal growth factor receptor, cells and methods for their production and compositions containing them
CN108025083A (en) Glyco-engineered antibody drug conjugate
CN106471010A (en) The locus specificity of targeting module is Glyco-engineered
WO2007073499A3 (en) Epha2 bite molecules and uses thereof
ES2909720T3 (en) Combination therapy with an anti-CD19 antibody and a purine analog
BR112021011014A2 (en) ANTI-CLAUDINE ANTIBODIES AND USES THEREOF
WO2005055936A3 (en) Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
CN113711036A (en) anti-GAL 3 antibodies and uses thereof
WO2006110745A3 (en) Conjugated anti-psma antibodies
WO2006116451A3 (en) Antibodies with immune effector activity and that internalize in endosialin-positive cells
CA3188508A1 (en) Antibody drug conjugate
WO2021090062A8 (en) Anti-mesothelin eribulin antibody-drug conjugates and methods of use
WO2007144046A3 (en) Agent for the treatment of malignant diseases
WO2023215746A9 (en) Anti-alppl2 antibodies and chimeric antigen receptors, and compositions and methods of use
WO2021067633A3 (en) Kir3dl3 is an inhibitory receptor of the immune system and uses thereof
IL138021A0 (en) High affinity humanized anti-tag-72 monoclonal antibodies
WO2022221844A3 (en) Improved chimeric antigen receptors and uses thereof
NZ225280A (en) Human tumor cell epitope and antigen recognised by monoclonal antibody 16-88, the antibody and their use
GR3020387T3 (en) Ctaa 28a32, the antigen recognized by mca 28a32

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23800172

Country of ref document: EP

Kind code of ref document: A2